SWOG clinical trial number
SWOG-9323 (E4592)
Laboratory/Clinical Correlative Studies in Non-Small Cell Lung Cancer: Ancillary Study to SWOG-9252 (INT-0115, E3590, RTOG-91-05, NCCTG 91-24-51)
Closed
Phase
Published
Abbreviated Title
Laboratory/Clinical Correlative Studies in Non-Small Cell Lung Cancer: Ancillary Study to SWOG-9252 (INT-0115, E3590, RTOG-91-05, NCCTG 91-24-51)
Activated
03/01/1994
Closed
12/01/1996
Research committees
Lung Cancer
Publication Information Expand/Collapse
2001
Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a lab ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postop adjuvant therapy
1999
Prognostic significance of p53 and K-RAS mutations in primary resected non-small cell lung cancer: Preliminary results from a propsective randomized trial of postoperative adjuvant therapy (intergroup trial 0115).
Other Clinical Trials
SWOG Clinical Trial Number
A082302
EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)
Research Committee(s)
Lung Cancer
Activated
03/02/2027
Open
SWOG Clinical Trial Number
S2409
PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231
A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase